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SELECTION OF THE MONTH 
Big Title: Tea and coffee are good for the liver 
 
Small titles: Novel PET tracer to visualize biliary tree  
A potential high-risk mutation for HBV-infected individuals 
Global epidemiology of HCV subtypes and resistance-associated substitutions 
Trends in HCV incidence among HIV-positive MSM 
 
METABOLIC LIVER DISEASES 
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Cyclic AMP-dependent activating transcription factor ATF-3, beta-catenin and 
CD44: new molecular drivers of NASH and iron-overload induced liver injury 
Cyclic AMP-dependent activating transcription factor 3 ATF-3 (encoded by ATF3 and 
hereafter called ATF-3) plays a role in type 2 diabetes and insulin resistance. In this 
issue of the Journal, Kim et al. studied its role in NAFLD. ATF-3 was highly expressed 
in the liver from patients with NAFLD and in Zucker diabetic fatty (ZDF) rats. Insulin 
resistance and hepatic steatosis were associated with increased ATF-3 expression 
and decreased fatty acid oxidation. Importantly, Atf3 suppression ameliorated 
glucose intolerance and inflammatory responses in ZDF rats. In patients with 
NAFLD, ATF-3 expression correlated with surrogate markers of type 2 diabetes and 
hepatic inflammation. Collectively, the results of this translational study suggest a role 
for ATF-3 in insulin resistance and hepatic inflammation in patients with NAFLD and 
represents a novel target for therapy. In another interesting study, Preziosi et al. 
studied the link between beta-catenin (encoded by Ctnnb1 in mice), iron overload and 
liver injury. Ctnnb1-knockout mice were exposed to an iron-overload diet in the 
presence or absence of NAC, an antioxidant agent. Ctnnb1-deficient mice expose 
to iron exhibited remarkable inflammation, fibrosis and occurrence of 
occasional HCC. Interestingly, antioxidant therapy ameliorated this changes, Addition 
of NAC to drinking water protected mice from liver injury and prevented the 
activation of pro-inflammatory signaling pathways.  This study reveals a new role for 
beta-catenin and suggests that antioxidants may have a protective role against iron-
induced liver injury. Finally, another study from this issue analyzes the role of CD44, a 
receptor that regulates adipose tissue inflammation in obesity. Patouraux et al. provide 
elegant evidence that mice deficient in CD44 antigen (Cd44) are resistant to develop 
liver inflammation and fibrosis after a fibrogenic insult. Interestingly, Cd44 deficiency 
enhanced the M2 polarization and strongly decreased the activation of macrophages 
by lipopolysaccharide, hepatocyte damage-associated molecular patterns, and 
saturated fatty-acids. Neutralization of CD44 antigen protein decreased macrophage 
infiltration. Importantly, in NASH patients hepatic CD44 and soluble CD44 antigen in 
serum was increased and correlated with the severity of liver injury. This study 
suggests that CD44 is a biomarker and a molecular player in NASH by regulating 
macrophage infiltration and polarization.  
 
LIVER FIBROSIS 
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Coffee and herbal tea consumption is protective of liver stiffness in the general 
population 
Coffee and tea have been proposed to have beneficial effects on liver diseases 
including HCC development. Alferink et al. analyzed the participants who underwent 
transient elastography, ultrasound and completed a food frequency questionnaire 
from the Rotterdam study, a large prospective population-based cohort. The authors 
included 2,424 participants of whom 5 % had LSM ≥ 8.0kPa and 34% steatosis. 
Proportion of LSM ≥ 8.0kPa decreased with higher coffee consumption. 
Amongst tea consumers, only herbal tea consumers (36%) had lower log-
transformed transient elastography levels. Subtypes of tea were associated with 
steatosis in univariate but not multivariable analysis. This important epidemiological 
study suggests that in the general population, frequent coffee and herbal tea 
consumption are inversely related with liver stiffness but not steatosis. This results 
should be confirmed in prospective longitudinal studies.  
 
HEPATITIS C VIRUS (HCV) INFECTION  
Global epidemiology of HCV subtypes and resistance-associated substitutions, 
next generation pangenotypic DAA combination, trends in HCV incidence 
among HIV-positive MSM, scavenger receptor class B member 1 genetic 
variants modulate HCV infection  
HCV genotypes and subtypes as well as the presence of baseline resistance-
associated substitutions (RASs) represent key viral determinants for the selection of 
direct-acting antiviral (DAA) treatment regimens. The study by Welzel et al. is the first 
comprehensive global molecular epidemiology analysis of HCV subtypes and subtype-
specific RASs. The analyses were performed by both, INNO-LiPA and sequencing on 
12,615 patient samples from 28 different countries across five geographic regions. 
Whereas genotyping concordance was high between both methods, the INNO-LiPA 
had significant limitations in subtyping especially of the types 2, 3, 4 and 6. The 
observed variations in regional subtype epidemiology but also subtype-specific 
RAS prevalence may have crucial implications when designing future global 
HCV treatment strategies. 
Aiming for antiviral regimens being highly effective irrespective of the HCV 
type/subtype and presence of baseline resistance-associated variants was the 
rationale behind second generation DAA drug development. The NS3/4A protease 
4 
 
inhibitor glecaprevir and NS5A inhibitors pibrentasvir (G/P) have potent antiviral activity 
in vitro against all six major HCV genotypes with a high barrier to the selection of 
common viral variants with resistance-associated substitutions. In this issue of the 
Journal, Kwo et al. present results from two phase 2 studies (SURVEYOR-I and 
SURVEYOR-II, parts 1 and 2) designed to evaluate the efficacy and safety of various 
doses of G/P with or without ribavirin for the treatment of non-cirrhotic patients with 
HCV genotype 1, 2, 3, 4, 5, or 6 infection. Eight-week treatment with the dosage-
optimized regimen yielded SVR rates of 97-98% in HCV type 1-3 infection (with no 
virologic relapses), and 100% of type 4-6 infected patients achieved SVR after a 12 
week course. These studies demonstrate the ability of the G/P combination to 
treat all six major HCV genotypes with a single ribavirin-free regimen regardless 
of baseline resistance-associated polymorphisms, and with treatment durations 
as short as eight weeks in populations without cirrhosis. 
HCV infection continues to spread among HIV-positive men who have sex with men 
(MSM), especially among younger individuals. This cohort study from Europe, 
Australia and Canada aims at estimating trends in HCV incidence among HIV-positive 
MSM with well-estimated dates of HIV seroconversion from the CASCADE 
Collaboration, but also assessed the association between HCV incidence and 
geographical region, age, HIV RNA and CD4 count. Van Santen et al. showed that 
HCV incidence significantly increased after 1990 and there was no evidence of a 
decline in recent years. However, trends seem to differ by geographical region. 
While HCV incidence appears to have stabilized in Western Europe, and remained 
stable in Southern Europe, an increase in HCV incidence was observed in Northern 
Europe. Interestingly, a higher HIV RNA and younger age were associated with a 
higher HCV incidence. This large-scale study adds important data to the current body 
of evidence regarding HCV trends among HIV-positive MSM and on the association of 
HIV-related factors with HCV infection. 
Scavenger receptor class B member 1 (SRB1) is one of four hepatocyte surface 
expressed molecules regarded as essential for HCV host cell entry. Physiologically, 
SRB1 functions as a multiligand receptor that binds lipoproteins. Numerous studies 
indicate that genetic variations in the SCARB1 gene that encodes SRB1 are 
associated with clinical phenotypes, yet their impact on HCV infection is incompletely 
understood. Westhaus et al. performed the most comprehensive study to date 
evaluating the impact SCARB1 genetic variants on the molecular biology of HCV and 
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the clinical course of hepatitis C. They found evidence that both coding and non-
coding genetic variants affect the HCV replication cycle as well as clinically 
relevant HCV-related parameters in HCV infected individuals. Moreover, genetic 
deletion of SCARB1 from an HCV permissive cell line results in a markedly reduced 
susceptibility to HCV infection. Overall, this important study add to our understanding 
on the role of genetic host factors in modulating the disease characteristics herby 
explaining - at least in part - the remarkable high degree of inter-individual variations 
seen in the course of HCV infection. 
 
HEPATITIS B VIRUS (HBV) INFECTION 
A potential high-risk mutation for HBV-infected individuals selected during TDF 
and ETV combination therapy 
Long-term treatment with antiviral drugs carries the risk of selecting mutations in the 
HBV polymerase. Tacke et al. report two cases of patients with insufficient response 
to dual tenofovir (TDF) and entecavir (ETV) therapy in whom ultra-deep 
pyrosequencing analyses revealed the selection of the rtS78T polymerase mutation. 
Interestingly, the rtS78T polymerase mutation causes enhanced viral replication, 
and reduced susceptibility to ETV and TDF in vitro, and creates a premature stop 
codon at sC69 which causes truncation of the hepatitis B surface protein 
(HBsAg), thereby deleting almost the entire small HBsAg. These interesting 
findings will stimulate further research in order to define the role of this pontential high-
risk mutation with respect to nucleos(t)ide-analog treatment failure and HBV-related 
carcinogenesis. 
 
BILIARY IMAGING  
Development of a novel PET tracer to visualize the biliary tree 
Bile acid flow and signaling is fast becoming important target for new drug 
development. Imaging techniques aimed at evaluating bile flow are limited. The study 
by Ørntoft et al. aimed to use a radiolabelled conjugated bile acid tracer [N- methyl-
11C] cholylsarcosine (11C-CSar), that they developed for quantification of 
hepatobiliary secretion in healthy volunteers and patients with cholestatic liver 
diseases using PET scanning. The authors provide the exciting novel method 
and data that allows accurate quantification of bile acid kinetics that will be 
revolutionary in providing better understanding of the pathophysiology of 
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cholestatic diseases. 
 
BILIRUBIN HEPATOXICITY 
Bilirubin breakdown products, Z-BOX A and Z-BOX B are hepatotoxic 
It is well known that in conditions of severe cholestasis, bilirubin can have cytotoxic 
effects but the mechanism is unclear. Under conditions of oxidative stress, 
unconjugated bilirubin is oxidized to higher-order degradation products such as the 
major bilirubin oxidation end products (BOXes) but its role in mediating further liver 
injury is unknown. The paper from Seidel et al. provides measurements of these 
metabolites in health and in patients with liver failure. They show for the first 
time that there are detectable levels of these Z-BOXes in healthy individuals 
and markedly increased in patients with liver failure. They also show that these 
substances can induce dose dependent cytotoxicity and glutathione depletion. 
These novel data provide exciting new insight into the pathogenesis of liver injury 
and potential therapeutic target. 
 
HEPATOCELLULAR CARCINOMA (HCC) 
OGT uses palmitate and ER stress to promote HCC in NAFLD, targeted deep 
sequencing for circumventing tumor heterogeneity, tumor-associated 
microparticles as biomarkers for cancer, global HCC epidemiology  
O-linked N-acetylglucosamine (GlcNAc) transferase (symbol OGT) encodes a glycosyl 
transferase involved in metabolism reprogramming. OGT, has been shown to be 
upregulated in tissues non-alcoholic fatty liver disease (NAFLD)-associated-HCC 
(NAFLD-HCC). Xu et al. here address the oncogenic role of OGT in NAFLD-HCC by 
investigating the effects of Ogt gain- or loss- of function in vitro and in nude mice. They 
reveal that OGT plays an oncogenic role in NAFLD-HCC through regulating 
palmitic acid and inducing ER stress, consequently activating oncogenic JNK/c-
jun/AP-1 and NF-κB cascades. 
In HCC, intratumoral heterogeneity challenges the identification of mutations which 
may be targets for therapies. Using whole-exome sequencing and targeted-deep 
sequencing (TDS), Huang et al. now show that TDS of single tumor specimen could 
largely circumvent intratumoral heterogeneity and uncover actionable 
mutations indicative of target therapy in HCC.  
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It has been shown that tumor-associated microparticles (taMPs) bearing annexin V, 
Ep-CAM (for epithelial cell adhesion molecule), and CD147 (recommended name, 
basigin) can be used as biomarkers for cancer. Julich-Haertel et al. investigated taMPs 
in the context of HCC and cholangiocarcinoma (CCA). They enrolled a large series of 
patients with liver cancer (HCC or CCA), cirrhosis (without cancer), and control 
subjects, and performed fluorescence-activated cell scanning to detect taMPs in the 
serum. They show that taMPs bearing Annexin V, EpCAM, and ASGPR 1 can be 
considered as a novel biomarker of HCC and CCA liquid biopsy that permit a 
non-invasive assessment of the presence and possibly the extent of these 
cancers in patients with advanced liver diseases. Of note, ASGPR 1 is the short 
name for asialoglycoprotein receptor 1 (encoded by ASGR1, belonging to the C-type 
lectin domain containing [CLEC] gene family). 
In this issue of the Journal, Bertuccio et al. report the results of their updating of global 
trends in HCC mortality to 2014, and predict trends in rates in the European Union, 
Unites-States of American, and Japan to 2020, using data from the World Health 
Organization database. They show that HCC mortality falls in Eastern Asia and 
Southern Europe mainly because of the control of HBV and HCV virus infections. 
There is an unfavorable trends in other areas of the world due to HCV (and HBV) 
epidemics between the 60s and 80s, changes in alcohol consumption, and 
increased overweight/obesity, and consequently diabetes. Improvements in the 
management of cirrhosis and in HCC diagnosis and treatment account for part of the 
mortality trends worldwide. 
 
